Biotech News
Related news
PCVXVaxcyte2026-03-18 23:34 EST
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
PCVXVaxcyte2026-03-23 12:30 EST
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
GOVXGeoVax Labs2024-11-26 14:00 EST
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
VXRTVaxart2026-02-18 13:00 EST
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
GSKGSK plc2026-07-21 10:28 EST
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026
Vaxcyte
Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...
Recent company news
PCVXVaxcyte2026-08-05 20:05 EST
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
PCVXVaxcyte2026-07-08 20:05 EST
Vaxcyte to Participate in Upcoming Investor Conferences
PCVXVaxcyte2026-06-02 20:05 EST
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
PCVXVaxcyte2026-05-06 20:05 EST
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
PCVXVaxcyte2026-04-07 20:05 EST
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Stock data
- Close
- 58.89 USD
- Market cap
- 6.85B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States